Raymond James Financial Inc. Has $33.56 Million Stake in Charles River Laboratories International, Inc. $CRL

Key Points

• Raymond James Financial Inc. has reduced its stake in Charles River Laboratories by 3.8%, now owning 0.45% of the company worth approximately $33.56 million.
• Several institutional investors, including Rothschild Investment LLC and Parallel Advisors LLC, have significantly increased their stakes in Charles River Laboratories this quarter.
• Equity analysts have largely upgraded their ratings for the company, with five giving it a "Buy" rating and an average price target now set at $175.69.

Raymond James Financial Inc. lowered its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 3.8% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 222,959 shares of the medical research company's stock after selling 8,761 shares during the quarter. Raymond James Financial Inc. owned 0.45% of Charles River Laboratories International worth $33,560,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in CRL. Two Sigma Securities LLC boosted its position in shares of Charles River Laboratories International by 4.3% during the 4th quarter. Two Sigma Securities LLC now owns 1,981 shares of the medical research company's stock worth $366,000 after acquiring an additional 81 shares in the last quarter. Wahed Invest LLC lifted its holdings in shares of Charles River Laboratories International by 6.5% in the 4th quarter. Wahed Invest LLC now owns 1,321 shares of the medical research company's stock valued at $244,000 after purchasing an additional 81 shares during the last quarter. Teachers Retirement System of The State of Kentucky lifted its holdings in shares of Charles River Laboratories International by 2.7% in the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 3,916 shares of the medical research company's stock valued at $589,000 after purchasing an additional 102 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Charles River Laboratories International by 2.6% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,131 shares of the medical research company's stock valued at $763,000 after purchasing an additional 105 shares during the last quarter. Finally, Veracity Capital LLC lifted its holdings in shares of Charles River Laboratories International by 3.4% in the 1st quarter. Veracity Capital LLC now owns 3,298 shares of the medical research company's stock valued at $496,000 after purchasing an additional 107 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Trading Up 0.0%

Shares of Charles River Laboratories International stock traded up $0.07 on Friday, reaching $163.29. 860,239 shares of the company were exchanged, compared to its average volume of 954,372. The stock has a fifty day moving average price of $159.32 and a 200-day moving average price of $148.81. The firm has a market capitalization of $8.04 billion, a price-to-earnings ratio of -122.77, a price-to-earnings-growth ratio of 5.21 and a beta of 1.48. Charles River Laboratories International, Inc. has a fifty-two week low of $91.86 and a fifty-two week high of $230.02. The company has a current ratio of 1.36, a quick ratio of 1.10 and a debt-to-equity ratio of 0.69.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its earnings results on Wednesday, August 6th. The medical research company reported $3.12 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.50 by $0.62. The company had revenue of $1.03 billion during the quarter, compared to analyst estimates of $983.76 million. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.The company's revenue for the quarter was up .6% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.80 earnings per share. On average, analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Insider Activity

In related news, EVP Joseph W. Laplume sold 800 shares of the stock in a transaction on Monday, August 18th. The stock was sold at an average price of $157.60, for a total transaction of $126,080.00. Following the completion of the sale, the executive vice president directly owned 24,116 shares in the company, valued at approximately $3,800,681.60. This trade represents a 3.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.30% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on CRL. TD Cowen raised Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 target price for the company in a research note on Wednesday, May 14th. JPMorgan Chase & Co. increased their target price on Charles River Laboratories International from $145.00 to $160.00 and gave the company a "neutral" rating in a report on Thursday, August 7th. Robert W. Baird raised their price objective on Charles River Laboratories International from $118.00 to $140.00 and gave the stock a "neutral" rating in a report on Thursday, May 8th. Redburn Atlantic upgraded Charles River Laboratories International from a "neutral" rating to a "buy" rating and reduced their target price for the company from $188.00 to $182.00 in a report on Friday, May 23rd. Finally, Barclays lifted their target price on Charles River Laboratories International from $155.00 to $165.00 and gave the company an "equal weight" rating in a report on Thursday, August 7th. Five analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $175.69.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).